We are live on ! Find out more
ASND icon

Ascendis Pharma A/S
ASND

244 hedge funds and large institutions have $10.1B invested in Ascendis Pharma A/S in 2025 Q1 according to their latest regulatory filings, with 54 funds opening new positions, 77 increasing their positions, 88 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 24

16% more capital invested

Capital invested by funds: $8.78B → $10.1B (+$1.37B)

14% more funds holding

Funds holding: 214 → 244 (+30)

1.54% more ownership

Funds ownership: 105.86% → 107.4% (+1.5%)

0% more funds holding in top 10

Funds holding in top 10: 14 → 14 (0)

13% less repeat investments, than reductions

Existing positions increased: 77 | Existing positions reduced: 88

38% less call options, than puts

Call options by funds: $23.8M | Put options by funds: $38.3M

Holders
244
Holders Change
+30
Holders Change %
+14.02%
% of All Funds
3.27%
Holding in Top 10
14
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.19%
New
54
Increased
77
Reduced
88
Closed
24
Calls
$23.8M
Puts
$38.3M
Net Calls
-$14.5M
Net Calls Change
+$6.32M

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$154M
2
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$46.9M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$46.8M
4
Franklin Resources
Franklin Resources
California
+$40.5M
5
Citadel Advisors
Citadel Advisors
Florida
+$32.7M

Top Sellers

Rank Fund Capital Flow
1
CCM
Camber Capital Management
Massachusetts
-$64.3M
2
VPC
Vestal Point Capital
New York
-$52.8M
3
Fidelity International
Fidelity International
Bermuda
-$38.1M
4
Artisan Partners
Artisan Partners
Wisconsin
-$27.7M
5
BlackRock
BlackRock
New York
-$19.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
ETCM
101
Evolutionary Tree Capital Management
Virginia
$3.22M -$1.35M -9,459 -31%
D.E. Shaw & Co
102
D.E. Shaw & Co
New York
$3.2M -$2.49M -17,454 -46%
CI
103
Capital International
California
$3.15M +$150K +1,048 +5%
EAM
104
Erste Asset Management
Austria
$3.14M – – –
SIA
105
Sit Investment Associates
Minnesota
$3.02M – – –
Two Sigma Investments
106
Two Sigma Investments
New York
$2.92M +$1.12M +7,846 +72%
HighTower Advisors
107
HighTower Advisors
Illinois
$2.81M +$2.07M +14,518 +413%
HJIM
108
Henry James International Management
New York
$2.78M – – –
VOYA Investment Management
109
VOYA Investment Management
Georgia
$2.75M – – –
SGA
110
Sector Gamma AS
Norway
$2.65M +$2.43M +17,000 New
Stifel Financial
111
Stifel Financial
Missouri
$2.51M -$143K -1,001 -6%
Walleye Capital
112
Walleye Capital
New York
$2.47M +$2.26M +15,837 New
SC
113
Stempoint Capital
New York
$2.3M +$2.1M +14,732 New
NFGH
114
Nan Fung Group Holdings
Hong Kong
$2.12M – – –
CCIA
115
Campbell & Co Investment Adviser
Maryland
$2.03M +$1M +7,001 +116%
CUAMC
116
China Universal Asset Management Company
China
$1.89M -$96.6K -676 -5%
PE
117
Point72 Europe
United Kingdom
$1.88M +$1.72M +12,053 New
Envestnet Asset Management
118
Envestnet Asset Management
Illinois
$1.85M +$182K +1,274 +12%
EGM
119
Engineers Gate Manager
New York
$1.84M +$722K +5,052 +75%
Handelsbanken Fonder
120
Handelsbanken Fonder
Sweden
$1.8M -$300K -2,100 -15%
Susquehanna International Group
121
Susquehanna International Group
Pennsylvania
$1.78M -$2.64M -18,465 -62%
AC
122
Aristeia Capital
Connecticut
$1.76M +$71.4K +500 +5%
Barclays
123
Barclays
United Kingdom
$1.62M -$2.65M -18,586 -64%
AAM
124
Advisors Asset Management
Colorado
$1.43M +$136K +949 +12%
CII
125
Capital International Inc
California
$1.39M +$82.1K +575 +7%
3 4
5
6 7

ASND Hedge Fund Activity: Q1 2025 in Review

244 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q1 2025, worth a combined $10.1B — up 16% from $8.78B a quarter earlier.

Buyers outnumbered sellers: 54 funds opened new ASND positions and 24 closed out — a net gain of 30 holders — while 77 added to existing stakes and 88 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $154M. The largest seller was Camber Capital Management, cutting an estimated $64.3M.

  • 244 institutional investors held Ascendis Pharma A/S (ASND) as of Q1 2025, up from 214 in Q4 2024.
  • Funds reported $10.1B of Ascendis Pharma A/S stock for Q1 2025, up 16% quarter-over-quarter.
  • 54 funds opened new Ascendis Pharma A/S positions in Q1 2025 and 24 closed out, a net change of +30 holders.
  • The largest Ascendis Pharma A/S buyer in Q1 2025 was Morgan Stanley, an estimated $154M added.
  • The largest Ascendis Pharma A/S seller in Q1 2025 was Camber Capital Management, an estimated $64.3M sold.

Based on aggregated 13F filings for Q1 2025.